MAPK1 and renal carcinoma: ERK2 can phosphorylate TOPK/PBK to promote tumorigenesis and participate in sorafenib resistance of renal cancer [41]; ERK2-induced PDHE1α phosphorylation and subcellular translocation promote tumor immune escape [42].